Everolimus
NDC product · U.S. Food and Drug Administration (openFDA) · United States
-
Product NDC
51991-992 -
Package NDC
51991-992-28 -
Package NDC
51991-992-77 -
Application number
ANDA217640 -
SPL ID
fade73fb-a367-4c53-83dd-1352c3ad807b -
SPL set ID
01f7b5fb-be0d-4adf-acd2-6899018de966 -
UNII
9HW64Q8G6G -
RxCUI
845507 -
RxCUI
845515 -
RxCUI
998189 -
RxCUI
1119400 -
RxCUI
1308428 -
RxCUI
1308430 -
RxCUI
1308432
What the source publishes
- Labeler
- Breckenridge Pharmaceutical, Inc.
- Active ingredients
- Everolimus
- Form
- TABLET, FOR SUSPENSION
- Routes
- ORAL
- Administrative status
- present-in-source-snapshot
- Marketing status
- ANDA
- Product type
- HUMAN PRESCRIPTION DRUG
- Prescription
- Prescription or restricted
Names this record is found by
Complete source data
{
"name": "Everolimus",
"splId": "fade73fb-a367-4c53-83dd-1352c3ad807b",
"labels": [
{
"setId": "01f7b5fb-be0d-4adf-acd2-6899018de966",
"labelUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01f7b5fb-be0d-4adf-acd2-6899018de966",
"labelPdfUrl": "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=01f7b5fb-be0d-4adf-acd2-6899018de966"
}
],
"routes": [
"ORAL"
],
"labeler": "Breckenridge Pharmaceutical, Inc.",
"finished": true,
"packaging": [
{
"sample": false,
"description": "4 BLISTER PACK in 1 CARTON (51991-992-28) / 7 TABLET, FOR SUSPENSION in 1 BLISTER PACK (51991-992-99)",
"package_ndc": "51991-992-28",
"identifierStatus": "well-formed",
"marketing_start_date": "20250128"
},
{
"sample": false,
"description": "28 TABLET, FOR SUSPENSION in 1 BOTTLE (51991-992-77)",
"package_ndc": "51991-992-77",
"identifierStatus": "well-formed",
"marketing_start_date": "20250731"
}
],
"productId": "51991-992_fade73fb-a367-4c53-83dd-1352c3ad807b",
"useDomain": "unknown",
"dosageForm": "TABLET, FOR SUSPENSION",
"productNdc": "51991-992",
"deaSchedule": null,
"genericName": "Everolimus",
"productType": "HUMAN PRESCRIPTION DRUG",
"listingStatus": "present-in-source-snapshot",
"targetSpecies": [],
"approvalStatus": "not-established-by-ndc-listing",
"labelAssociation": "openFDA-harmonized-set-ids; not a product-level approval match",
"marketingEndDate": null,
"activeIngredients": [
{
"name": "EVEROLIMUS",
"strength": "5 mg/1"
}
],
"applicationNumber": "ANDA217640",
"marketingCategory": "ANDA",
"stateRestrictions": {
"status": "not-collected",
"observations": []
},
"useDomainEvidence": {
"basis": "unreviewed",
"field": null,
"value": null,
"version": 1,
"sourceId": "us.fda.ndc"
},
"marketingStartDate": "20250128",
"targetSpeciesStatus": "not-reported",
"prescriptionCategory": "prescription-or-restricted",
"harmonizedIdentifiers": {
"nui": [
"N0000175605",
"N0000175076",
"N0000182141",
"N0000182137",
"N0000175625",
"N0000175624",
"N0000175550"
],
"upc": [
"0351991822332",
"0351991823339",
"0351991824336",
"0351991821335"
],
"unii": [
"9HW64Q8G6G"
],
"rxcui": [
"845507",
"845515",
"998189",
"1119400",
"1308428",
"1308430",
"1308432"
],
"spl_set_id": [
"01f7b5fb-be0d-4adf-acd2-6899018de966"
],
"pharm_class_pe": [
"Decreased Immunologic Activity [PE]"
],
"pharm_class_epc": [
"Kinase Inhibitor [EPC]",
"mTOR Inhibitor Immunosuppressant [EPC]"
],
"pharm_class_moa": [
"Protein Kinase Inhibitors [MoA]",
"Cytochrome P450 3A4 Inhibitors [MoA]",
"Cytochrome P450 2D6 Inhibitors [MoA]",
"mTOR Inhibitors [MoA]"
],
"manufacturer_name": [
"Breckenridge Pharmaceutical, Inc."
],
"is_original_packager": [
true
]
},
"listingExpirationDate": "20261231"
}
Read this record from your own software
The same record, with every field and its provenance, is one request away. An API key is free and works immediately.
curl -G "https://api.medifontis.com/v1/drugs/record" \
-H "Authorization: Bearer $MEDIFONTIS_API_KEY" \
--data-urlencode "country=us" \
--data-urlencode "sourceId=us.fda.ndc" \
--data-urlencode "id=us:fda:ndc:51991-992_fade73fb-a367-4c53-83dd-1352c3ad807b"